This proposal leverages our novel, unprecedented, and unique method for editing the mitochondrial genome. B-MoGen has exclusive license to this technology. This proposal will finally provide the final piece to complete the human genome project from a functional perspective since it has been impossible to make targeted gene knockouts in the mitochondrial genome until now. This is critically important given that the mitochondria play pivotal roles in human biology and disease. Indeed, there are many mitochondrial genetic diseases that have been impossible to model in isogenic pairs of cells. In this proposal, we will generate human cell lines, including a human induced pluripotent stem (iPS) cell line, that carry a mitochondrial genome deletion present in the most common human mitochondrial genetic disease called Kearns-Sayre Syndrome (KSS). We will employ our mitoTALE-nickases to introduce 4.9kb deletions spanning position 8469 to position 13147 in the mitochondrial genomes in these cells. We will employ our mitoTALENs to induce heteroplasmic shift of the mitochondrial genomes to those carrying the deletion. Secondly, we will develop tools to make doxycycline and cumate inducible mitoTALEN vectors for allowing conditional generation of mitochondrial deletions and induction of heteroplasmic shift. Finally, we will generate mitoTALE-nickases to target each of the 13 protein encoding components of the mitochondrial genome and each of the 2 encoded ribosomal RNAs (rRNA) in both mouse and human cells.

Public Health Relevance

Although there have been significant advancements in gene editing over the past two decades, none have been able to precisely edit the mitochondrial genome, until now. The goal of the proposed project is to use mitochondrial gene editing technology we have acquired to generate a set of tools and reagents to create human and mouse cell lines that carry a deletion in each protein and ribosomal RNA encoded on the mitochondrial genome. The result of this proposal will provide researchers with a novel set of tools necessary to better understand and interrogate mitochondria biology and disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43GM125462-01
Application #
9406532
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Marino, Pamela
Project Start
2017-08-01
Project End
2019-01-31
Budget Start
2017-08-01
Budget End
2019-01-31
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
B-Mogen Biotechnologies, Inc.
Department
Type
DUNS #
079960066
City
Minneapolis
State
MN
Country
United States
Zip Code
55413